Research and Markets: Choroidal Neovascularization - Pipeline Analysis & Review, H2 2015
28 November 2015 - 1:45AM
Business Wire
Research and Markets
(http://www.researchandmarkets.com/research/kxvtp3/choroidal) has
announced the addition of the "Choroidal Neovascularization -
Pipeline Review, H2 2015" report to their offering.
The report, Choroidal Neovascularization - Pipeline Review, H2
2015, provides an overview of the Choroidal Neovascularization's
therapeutic pipeline. This report provides comprehensive
information on the therapeutic development for Choroidal
Neovascularization, complete with comparative analysis at various
stages, therapeutics assessment by drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type, along with
latest updates, and featured news and press releases.
It also reviews key players involved in the therapeutic
development for Choroidal Neovascularization and special features
on late-stage and discontinued projects.
Key Topics Covered:
- Snapshot of the global therapeutic landscape of Choroidal
Neovascularization
- Key pipeline products under drug profile section which includes
product description, MoA and R&D brief, licensing and
collaboration details & other developmental activities
- Key players involved in the therapeutics development for
Choroidal Neovascularization and enlists all their major and minor
projects
- All dormant and discontinued pipeline projects
- Choroidal Neovascularization products under development by
companies and universities/research institutes based on information
derived from company and industry-specific sources
- Pipeline products coverage based on various stages of
development ranging from pre-registration till discovery and
undisclosed stages
- Detailed assessment of monotherapy and combination therapy
pipeline projects
- Coverage of the Choroidal Neovascularization pipeline on the
basis of target, MoA, route of administration and molecule
type
- Latest news and deals relating related to pipeline
products
Benefits of this Report:
- Provides strategically significant competitor information,
analysis, and insights to formulate effective R&D development
strategies
- Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain
competitive advantage
- Develop strategic initiatives by understanding the focus areas
of leading companies
- Identify and understand important and diverse types of
therapeutics under development for Choroidal
Neovascularization
- Plan mergers and acquisitions effectively by identifying key
players of the most promising pipeline
- Devise corrective measures for pipeline projects by
understanding Choroidal Neovascularization pipeline depth and focus
of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects
to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from
pipeline
Companies Mentioned:
- Affitech A/S
- Aprogen, Inc.
- F. Hoffmann-La Roche Ltd.
- Genentech, Inc.
- Iconic Therapeutics, Inc.
- Mabion SA
- Navigen Pharmaceuticals, Inc.
- Noxxon Pharma AG
- Promedior, Inc.
- Regeneron Pharmaceuticals, Inc.
- Sanwa Kagaku Kenkyusho Co., Ltd.
For more information visit
http://www.researchandmarkets.com/research/kxvtp3/choroidal
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151127005409/en/
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Sector: Pharmaceuticals